GKOS Insider Trading

Insider Ownership Percentage: 6.40%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $10,507,747.68

Glaukos Insider Trading History Chart

This chart shows the insider buying and selling history at Glaukos by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

Glaukos Share Price & Price History

Current Price: $90.15
Price Change: Price Increase of +1.352 (1.52%)
As of 04/17/2025 04:59 PM ET

This chart shows the closing price history over time for GKOS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$90.15Closing price on 04/17/25:

SEC Filings (Institutional Ownership Changes) for Glaukos (NYSE:GKOS)

99.04% of Glaukos stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at GKOS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$14Mbought$564ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$1B-$500M$0$500M$1BTotal InflowsTotal Outflows
Glaukos logo
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Read More on Glaukos

Today's Range

Now: $90.15
Low: $88.03
High: $91.43

50 Day Range

MA: $109.20
Low: $81.84
High: $161.30

52 Week Range

Now: $90.15
Low: $77.91
High: $163.71

Volume

662,537 shs

Average Volume

638,778 shs

Market Capitalization

$5.10 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Who are the company insiders with the largest holdings of Glaukos?

Glaukos' top insider investors include:
  1. Thomas William Burns (CEO)
  2. Joseph E Gilliam (COO)
  3. Tomas Navratil (Insider)
  4. Alex R Thurman (CFO)
  5. Marc Stapley (Director)
  6. Mark J Foley (Director)
  7. Gilbert H Kliman (Director)
  8. Aimee S Weisner (Director)
Learn More about top insider investors at Glaukos.

Who are the major institutional investors of Glaukos?

Glaukos' top institutional investors include:
  1. Rhumbline Advisers — 0.25%
  2. GAMMA Investing LLC — 0.24%
  3. Harbor Capital Advisors Inc. — 0.07%
  4. Yousif Capital Management LLC — 0.04%
  5. Handelsbanken Fonder AB — 0.03%
  6. Exchange Traded Concepts LLC — 0.01%
Learn More about top institutional investors of Glaukos stock.

Which institutional investors are selling Glaukos stock?

Within the previous quarter, GKOS stock was sold by these institutional investors:
  1. Trust Point Inc.
  2. Caldwell Sutter Capital Inc.
  3. GAMMA Investing LLC
  4. Yousif Capital Management LLC
  5. Rhumbline Advisers
During the previous year, company insiders that have sold Glaukos company stock include:
  1. Thomas William Burns (CEO)
  2. Joseph E Gilliam (COO)
  3. Tomas Navratil (Insider)
  4. Alex R Thurman (CFO)
  5. Marc Stapley (Director)
  6. Mark J Foley (Director)
Learn More investors selling Glaukos stock.

Which institutional investors are buying Glaukos stock?

Within the previous quarter, GKOS stock was purchased by institutional investors including:
  1. GAMMA Investing LLC
  2. Harbor Capital Advisors Inc.
  3. Handelsbanken Fonder AB
  4. Exchange Traded Concepts LLC
  5. Elevation Point Wealth Partners LLC
  6. SG Americas Securities LLC
  7. Versant Capital Management Inc
  8. Whipplewood Advisors LLC